| 1 |
Rösner E, Kaemmerer D, Sänger J, Lupp A. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Transl Oncol 2022;25:101526. [PMID: 36067541 DOI: 10.1016/j.tranon.2022.101526] [Reference Citation Analysis]
|
| 2 |
Chan D, Rodriguez-freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S. Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. European Journal of Cancer 2022;169:74-81. [DOI: 10.1016/j.ejca.2022.03.029] [Reference Citation Analysis]
|
| 3 |
Xu S, Ye C, Chen R, Li Q, Ruan J. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:2911. [PMID: 35740577 DOI: 10.3390/cancers14122911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Garcia-Alvarez A, Cubero JH, Capdevila J. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms? Curr Oncol Rep 2022. [PMID: 35171460 DOI: 10.1007/s11912-022-01235-x] [Reference Citation Analysis]
|
| 5 |
Corbett V, Arnold S, Anthony L, Chauhan A. Management of Large Cell Neuroendocrine Carcinoma. Front Oncol 2021;11:653162. [PMID: 34513663 DOI: 10.3389/fonc.2021.653162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Hiltunen N, Väyrynen JP, Böhm J, Helminen O. CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. Diseases 2021;9:42. [PMID: 34208144 DOI: 10.3390/diseases9020042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Lee W, Kim MJ, Choi Y, Kim H. PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis. Transl Cancer Res 2021;10:2210-8. [PMID: 35116539 DOI: 10.21037/tcr-20-3482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas 2021;50:500-5. [PMID: 33939660 DOI: 10.1097/MPA.0000000000001794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 9 |
Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
